Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

Tom Martin; Paul G Richardson; Thierry Facon; Philippe Moreau; Aurore Perrot; Ivan Spicka; Kamlesh Bisht; Marlene Inchauspé; France Casca; Sandrine Macé; Helgi Van de Velde; Kenshi Suzuki

doi:10.3324/haematol.2022.280660

Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

Haematologica. 2022 Oct 1;107(10):2485-2491. doi: 10.3324/haematol.2022.280660.

Authors

Affiliations

¹ UCSF Medical Center, San Francisco, CA. Tom.Martin@ucsf.edu.
² Dana-Farber Cancer Institute, Boston, MA.
³ Department of Haematology, Lille University Hospital, Lille.
⁴ Department of Hematology, University Hospital of Nantes, Nantes.
⁵ Centre Hospitalo-Universitaire (CHU) de Toulouse, Centre de Recherches en Cancérologie de Toulouse (CRCT), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Université de Toulouse, UPS, Toulouse.
⁶ First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic.
⁷ Sanofi, Research and Development, Cambridge, MA.
⁸ IT-M Statistics for Sanofi, Neuilly sur-Seine.
⁹ IVIdata for Sanofi, Levallois-Perret.
¹⁰ Sanofi, Research and Development, Vitry-Sur-Seine.
¹¹ Department of Hematology, Japanese Red Cross Medical Center, Tokyo.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Dexamethasone / therapeutic use
Humans
Multiple Myeloma* / drug therapy
Neoplasm Recurrence, Local / chemically induced
Neoplasm Recurrence, Local / drug therapy
Neoplasms, Plasma Cell*
Thalidomide / therapeutic use

Substances

Antibodies, Monoclonal, Humanized
Thalidomide
Dexamethasone
isatuximab

Grants and funding

Funding: Sanofi funded this sub-analysis of the ICARIA-MM and IKEMA studies. Medical writing support was provided by John Clarke, PhD, and Camile Semighini Grubor, PhD, on behalf of Elevate Medical Affairs, contracted by Sanofi for publication support services.